Sleep and Neurochemical Modulation by DZNep and GSK-J1: Potential Link With Histone Methylation Status

Eric Murillo-Rodríguez1,2*, Gloria Arankowsky-Sandoval3, Jorge Aparecido Barros2,4, Nuno Barbosa Rocha2,5, Tetsuya Yamamoto2,6, Sérgio Machado2,7, Henning Budde2,8,9, Diogo Telles-Correia2,10, Diogo Monteiro2,11,12, Luis Cid2,11,12 and André Barciela Veras2,4

Histone methylation/demethylation plays an important modulatory role in chromatin restructuring, RNA transcription and is essential for controlling a plethora of biological processes. Due to many human diseases have been related to histone methylation/demethylation, several compounds such as 3-deazaneplanocin A (DZNep) or 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; N-[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-β-Alanine (GSK-J1), have been designed to inhibit histone methylase or suppress histone demethylase, respectively. In the present study, we investigated the effects on the sleep-wake cycle and sleep-related neurochemical levels after systemic injections of DZNep or GSK-J1 given during the light or dark phase in rats. DZNep dose-dependently (0.1, 1.0, or 10 mg/kg, i.p.) prolonged wakefulness (W) duration while decreased slow wave sleep (SWS) and rapid eye movement sleep (REMS) time spent during the lights-on period with no changes observed in dark phase. In opposite direction, GSK-J1 (0.1, 1.0, or 10 mg/kg, i.p.) injected at the beginning of the lights-on period induced no statistical changes in W, SWS, or REMS whereas if administered at darkness, we found a diminution in W and an enhancement in SWS and REMS. Finally, brain microdialysis experiments in freely moving animals were used to evaluate the effects of DZNep or GSK-J1 treatments on contents of sleep-related neurochemicals. The results showed that DZNep boosted extracellular levels of dopamine, norepinephrine, epinephrine, serotonin, adenosine, and acetylcholine if injected at the beginning of the lights-on period whereas GSK-J1 exerted similar outcomes but when administered at darkness. In summary, DZNep and GSK-J1 may control the sleep-wake cycle and sleep-related neurochemicals through histone methylation/demethylation activity.

Keywords: adenosine, dopamine, histone demethylation, serotonin, sleep, wakefulness
INTRODUCTION

DNA methylation and modifications of histones are part of molecular mechanisms that control gene expression promoting the stabilization of the genome as well (Almeida et al., 2017; Bauer and Martin, 2017; Kim and Kaang, 2017; Pasculli et al., 2018). In the recent years, multiple studies have demonstrated the relationship between histone methylation/demethylation activity and various human pathologies, such as cancer (Zaidi et al., 2017; Zam and Khadour, 2017). Understanding the molecular mechanism by which histone methylation/demethylation is translated into molecular modulators is essential to developing medicinal approaches for disease genetics and genome-related medicine.

This research area is complex, but there is an increasing appreciation of the role of histones in health and disease. Current experimental pharmacological approaches for treating histone-related disorders are based on designed drugs aimed to manage genetic-related health disturbances (Li et al., 2016; Boehm and Ott, 2017; McCabe et al., 2017; Kaniskan et al., 2018; Khan and Haqqi, 2018; Thomas and D'Mello, 2018). Converging studies have suggested that compounds such as 3-deazaneplanocin A (DZNep), inhibits histone trimethylation of lysine 27 on histone H3 and lysine 20 on histone H4 whereas treatments with 3-[(6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino]propanoic acid; N-[(2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-β-Alanine (GSK-J1), the histone demethylation activity is suppressed (Dagdemir et al., 2016; Kuntz et al., 2016; Kaniskan et al., 2018; Zheng et al., 2018).

The histone methylation/demethylation activity is a promising target for exploring therapeutic options to treating multiple disorders. More recently, it has been demonstrated the role of histones in neurodegenerative diseases, aging, learning and memory (Jęsko et al., 2017; Kaluski et al., 2017; Zhao et al., 2018). Thus, the rationale use of histone methylation/demethylation inhibitors represents potential utility of DZNep or GSK-J1 in the comprehension of the role of histones in neurobiological processes, such as the sleep-wake cycle. In this report, we investigated the behavioral and neurochemical consequences that result from systemic injections of DZNep or GSK-J1, specifically in the sleep-wake cycle and extracellular levels of monoamines, adenosine and acetylcholine in rats.

MATERIALS AND METHODS

Experiment 1: Effects on Sleep After Injections of DZNep or GSK-J1 During the Lights-On or the Lights-Off Period

Ethics Statement

The whole experimental procedures were approved by the Research and Ethics Committee of our Institution fulfilling the Mexican Standards Related to Use and Management of Laboratory Animals (DOF. NOM-062-Z00-1999), the U.K. Animals Scientific Procedures (Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments), National Institute of Health (NIH Publication No. 80-23, revised 1996 and Guide for the Care and Use of Laboratory Animals, 8th Edn, 2011), and ARRIVE standards of Animal Welfare. For ethical reasons, efforts to minimize animal suffering were considered during the whole experiment and a reduced number of animals were included in the current report.

Animals

Male Wistar rats (n = 20; 250–300 g) were singly housed in polycarbonate cages (48.26 cm × 26.67 cm × 20.32 cm; Harlan Laboratories, Mexico) under humidity (60 ± 10%), ambient temperature (21 ± 1°C) and light–dark cycle 12:12 (lights-on: 07:00–19:00 h) controlled. All rats had free access to Purina Rat Chow (Purina, Mexico) as well as tap water.

Chemical

Chemical compounds studied in this article DZNep (PubChem CID: 73087); GSK-J1 (PubChem CID: 56963315); polyethylene glycol (PubChem CID: 174). More information is available at https://pubchem.ncbi.nlm.nih.gov/. DZNep and GSK-J1 were purchased from Sigma (St. Louis, MO, United States) and dissolved in a vehicle (VEH) solution composed of polyethylene glycol/saline (5:95 v/v) as previously reported (Mirandã et al., 2009; Johansson et al., 2016). Additional reagents, chemicals, and materials were purchased from Sigma-Aldrich (St. Louis, MO, United States) or Bioanalytical Systems (West Lafayette, IN, United States).

Sleep-Recording Surgeries

Anesthesia (acepromazine [0.75 mg/kg], xylazine [2.5 mg/kg], and ketamine [22 mg/kg]) was given (i.p.) to rats to place them in a stereotaxic frame (David Kopf Instruments, Tujunga, CA, United States) for sleep-recording electrodes surgery. Briefly, two stainless-steel screw electrodes were placed 2 mm on either side of the sagittal sinus and 3 mm anterior to Bregma (frontal cortex). Other two screws were located 3 mm on either side of the sagittal sinus and 6 mm behind Bregma (occipital cortex). The whole electrodes recorded the electroencephalogram (EEG) activity by the bipolar (differential) EEG recorded from the two contralateral screw electrodes (frontal-occipital). The electromyogram (EMG) activity was obtained by the implantation of two wire electrodes into the dorsal neck muscles. Finishing the EEG/EMG electrode implantation, the wires were inserted into a six-pin plastic plug (Plastics One, Roanoke, VA, United States) and attached onto the skull by dental cement. Upon completion of the EEG/EMG electrodes surgeries, animals were placed into individual cages with food and water ad libitum. In addition, rats were connected to a 6-channel slip-ring commutator through a 50 cm cable (Plastics One, Roanoke, VA, United States), which allowed free moving of animal around the cage. The EEG/EMG electrodes surgical procedure as well as habituation conditions were carried out as reported previously (Murillo-Rodríguez et al., 2017).
this period, animals were placed randomly into one of the experimental blocks (either lights-on or lights-off period): Control ([CTL] VEH; \( n = 5 \)), DZNep (0.1, 1.0, or 10 mg/kg, i.p.; each dose, \( n = 5 \)) or GSK-J1 (0.1, 1.0, or 10 mg/kg, i.p.; each dose, \( n = 5 \)). Doses of compounds were chosen arbitrarily since no direct evidence was available regarding their effects on freely moving rats. Moreover, the route of administration of compounds was selected to obtain a preliminary approach for an understanding of the putative phenomena. To avoid circadian influences in the pharmacological treatments of the histone methylation/demethylation activity on sleep, the administrations were done 1 h after either the start of the lights-on or the lights-off period. Thus, animals were disconnected from the sleep-recording system and experimental trials were administered. Once experimental challenges were applied, rats were reattached to the sleep-recording system and sleep data were collected across the next 4 h. Lastly, due to the reduced number of animals used for ethical reasons, the experiment was under a single-blind Latin Square Experimental Design. Since each subject serves as its own control, the testing paradigm has the advantage of decreasing variability among experimental conditions.

Analysis of Sleep Recordings
The sleep data were collected during the following 4 h post-injections sampled in periods of 12 s (epochs). Next, differentiation of wakefulness (W), slow wave sleep (SWS), or rapid eye movement sleep (REMS) was based on the characterization of each phase by the aid of the sleep-scoring program (ICELUS) as previously reported (Murillo-Rodríguez et al., 2017). One observer blind to the experiments analyzed sleep recordings.

Power Spectra Analysis
Fast Fourier transformation analysis for alpha (across W [\( \alpha = 12–16 \text{ Hz} \)], delta (for SWS [\( \Delta = 0.3–4.0 \text{ Hz} \)], and theta (during REMS [\( \Theta = 6.0–12.0 \text{ Hz} \)]) was collected during either lights-on or lights-off after experimental trials. This data provided information about quality rather than quantity of the sleep stages under the influence of treatments. Data were analyzed as previously reported (Murillo-Rodríguez et al., 2017). One observer blind to the experiments analyzed power spectra.

Statistical Analysis
The data for the experimental results were presented as mean ± SEM. The data were examined by ANOVA test followed by Scheffé’s post hoc test using the StatView software (version 5.0.0, SAS Institute, United States). Statistical differences among groups were determined if \( P < 0.05 \).

Experiment 2: Effects on the Extracellular Levels of Monoamines After Administrations of DZNep or GSK-J1 Animals
A new set of male Wistar rats (\( n = 20 \); 250–300 g) were maintained as described in Experiment 1.

Chemicals
As described in Experiment 1.

Microdialysis Surgeries
Previous results have shown the role of the nucleus accumbens (AcbC) in the sleep-wake cycle modulation (Qiu et al., 2012). Moreover, studies from our group have demonstrated reliable measurements of sleep-related neurochemicals such as dopamine (DA), norepinephrine (NE), epinephrine (EP), serotonin (5-HT), of samples collected from AcbC (Mijangos-Moreno et al., 2014, 2016; Murillo-Rodríguez et al., 2017). Thus, we determined whether DZNep or GSK-J1 might exert changes in the levels of these neurochemicals as characterized from microdialysis samples collected from AcbC. To achieve this goal, animals were anesthetized and mounted into the stereotaxic frame (David Kopf Instruments, Tujunga, CA, United States) for implantation of a microdialysis guide-cannula (IC guide; BioAnalytical Systems [BAS], West Lafayette, IN, United States) aimed unilaterally into the AcbC (coordinates: A = +1.2, L = +2.0, and H = −7.0 mm, with reference to Bregma [Paxinos and Watson, 2005]). Right after the surgery, rats were placed individually into the microdialysis bowl (Ranw Microdialysis Stand-Alone System, MD-1404, BAS, West Lafayette, IN, United States) for post-surgery recovery (seven continuous days) as well as habituation for the experimental conditions. All surgical procedures of microdialysis surgery were accomplished as previously reported (Murillo-Rodríguez et al., 2017).

Pharmacological Administrations
As described in Experiment 1.

Microdialysis Sampling Procedures
Once reaching the recovery and habituation time, animals were removed from microdialysis bowls and the stylet from guide-cannula was withdrawn. Next, the microdialysis probe (1 mm of length; polyacrylonitrile, MWCO = 30,000 Da; 340 \( \mu \text{m} \) OD; BAS, West Lafayette, IN, United States) was inserted at 07:00 h. Artificial cerebrospinal fluid (aCSF [composition: NaCl 147 mM, KCl 3 mM, CaCl 1.2 mM, MgCl 1.0 mM, pH 7.2]) was perfused through a miniature tube (0.65 mm OD × 0.12 mm ID; BAS, West Lafayette, IN, United States) attached to a 2.5 mL syringe (BAS, West Lafayette, IN, United States) with a pump (flow rate: 0.25 \( \mu \text{L} \)/min; BAS Bee, West Lafayette, IN, United States). As standardized procedure, before the beginning of the experiments, in all rats, the microdialysis membrane was stabilized during 24 h and samples from that period were excluded for the final analysis as suggested from previous reports (Mijangos-Moreno et al., 2014, 2016; Murillo-Rodríguez et al., 2017). Right after the period of stabilization of membrane was covered, experimental trials were given and animals were reattached to the microdialysis system. The dialysates were collected every 20 min at the beginning of each hour during the following 4 h. Later, all samples were stored (−80°C) for further analysis. The microdialysis sampling procedure was developed as previous reports (Mijangos-Moreno et al., 2014, 2016; Murillo-Rodríguez et al., 2017).
Neurochemical Analysis of Monoamines
Dialysates collected from sampling were filtered (Millipore 0.22 µm; Merck Millipore, Darmstadt, Germany) and injected into high performance liquid chromatography (HPLC; Modular Prominence, Shimadzu, Kyoto, Japan). For monoamines detection, the HPLC used mobile phase (monosodium phosphate) ([7 mM, pH 3.0], plus methanol [3.5%]) which was perfused at flow rate of 80 µL/min (pump LC-20AT, Shimadzu, Kyoto, Japan). Separation of molecules was achieved by using a microbore column (octadecyl silica [3 µm, 100 mm × 1 mm], BAS, West Lafayette, IN, United States) with temperature controlled (22°C; oven CTO-20A, Shimadzu, Kyoto, Japan). The detection of monoamines was obtained by using an electrochemical detector (LC-4C; BAS, West Lafayette, IN, United States). The chromatographic data were obtained and stored on a personal computer (via computer controller CBM-20A, Shimadzu, Kyoto, Japan). The concentrations of monoamines in the samples were obtained by comparing external known standards for the neurochemicals studied (DA, NE, EP and 5-HT) injected into HPLC. The whole HPLC procedures were developed as described previously (Murillo-Rodríguez et al., 2017). One observer blind to the code of experimental samples analyzed contents of monoamines.

Statistical Analysis
The total values for monoamines contents consisted in samples summed from continuous 4 h. All data from microdialysis experiments were represented as mean ± SEM. Statistical differences among the experimental groups were determined by one-way ANOVA followed by Scheffé’s post hoc test for multiple comparisons. All statistical analyses were performed using the StatView software (version 5.0.0, SAS Institute, United States) and statistical differences among groups were determined if P < 0.05.

Experiment 3: Effects on the Extracellular Contents of Adenosine After Treatments of DZNep or GSK-J1
Animals
As described in Experiment 2.

Chemicals
As described in Experiment 2.

Microdialysis Surgeries
As described in Experiment 2.

Administration of Drugs
As described in Experiment 1.

Microdialysis Sampling Method
As described in Experiment 2.

Neurochemical Analysis of Adenosine
Similar chromatographic conditions as described for detection of monoamines were used for adenosine (AD) analysis. Methodological differences consisted in using an UV detector (SPD-20A Prominence, Shimadzu, Kyoto, Japan) setting the wavelength at 254 nm (deuterium lamp) and mobile phase (10 mM sodium dihydrogen phosphate [pH 4.5] and methanol [9%]) which was perfused at a flow rate of 80 µL/min using a pump (LC-20AT, Prominence HPLC, Shimadzu, Kyoto, Japan). All chromatographic data for AD detection were recorded in a personal computer, and peak heights of this purine in dialysates were compared with external known standards by using chromatograph report software (LC Solution, Shimadzu, Kyoto, Japan). The whole procedure for detection and measurement of AD using HPLC means was developed according to previous reports (Mijangos-Moreno et al., 2014; Murillo-Rodríguez et al., 2017). Contents of AD were analyzed under a blind experimental design.

Statistical Analysis
As described in Experiment 2.

Experiment 4: Effects on the Extracellular Contents of Acetylcholine After Administrations of DZNep or GSK-J1

Animals
A new set of male Wistar rats (n = 20; 250–300 g) were used as described in Experiment 2.

Chemicals
As described in Experiment 1.

Microdialysis Surgeries
The importance of basal forebrain in the sleep-wake modulation has been previously reported (Anaclet et al., 2015; Gold et al., 2015; Xu et al., 2015). Moreover, it has been demonstrated that acetylcholine (ACh) is measurable from the mentioned brain area (Vanini et al., 2012; Zaghoul et al., 2017). Then, in this part of the study, we placed the microdialysis probe into the basal forebrain following stereotaxic coordinates (A = −0.35; L = 2.0; and H = −7.5 mm, with reference to Bregma [Paxinos and Watson, 2005]). All microdialysis surgery procedure was developed as described in Experiment 2.

Pharmacological Administrations
As described in Experiment 2.

Microdialysis Sampling Procedures
As described in Experiment 2 with exception of aCSF (KCl [2.4 nM], Na₂SO₄ [0.5 nM], NaCl [126.5 nM], CaCl₂ [1.2 nM], NaHCO₃ [27.5 nM], KH₂PO₄ [0.5 nM], MgCl₂ [0.8 nM], dextrose [5.0 nM] at pH [6.8 ± 0.1]) which was perfused through a miniature tubing (0.65 mm OD × 0.12 mm ID; BAS, West Lafayette, IN, United States) attached to a 2.5 mL syringe (BAS, West Lafayette, IN, United States) with a pump (flow rate: 2 µL/min; BAS Bee, West Lafayette, IN, United States).

Analysis of Contents of Acetylcholine Using the HPLC
As described in Experiment 2 with exception of conditions for ACh detection. In detail: neostigmine bromide (100 nM)
was added to the aCSF to facilitate detection of ACh contents. Moreover, the use of acetylcholine-choline assay kit (MF-8910; BAS, West Lafayette, IN, United States) was included for detection of ACh. Next, for separation of molecule, samples were injected into the HPLC at a flow rate of 1 mL/min, with temperature of 28°C (oven CTO-20A, Shimadzu, Kyoto, Japan), on 10 cm analytical column (MF-6150, BAS, West Lafayette, IN, United States) by using a mobile phase (Na$_2$HPO$_4$ [35 nM], EDTA [0.1 nM], and ProClin 150 preservative (0.005%), BAS, West Lafayette, IN, United States), and adjusted to pH 8.5 with phosphoric acid. By electrochemical means (LC-4C; BAS, West Lafayette, IN, United States) and maintaining the potential of +0.5 V, ACh was detected in collected samples. The analytical procedure to determine ACh was developed as previous reports (Grupe et al., 2013; Murillo-Rodríguez et al., 2018). Extracellular levels of ACh were analyzed under a blind experimental design.

**Recovery in vitro for Calibration of Microdialysis Probes**

In the whole microdialysis experiments, measuring monoamines, AD or ACh, the microdialysis probes were used no more than five continuous days since previous reports have shown that the permanence of the cannula in the study area for more than 5 days diminishes the membrane ability to transport fluid through the microdialysis probe pores (Porkka-Heiskanen et al., 2000; Murillo-Rodríguez et al., 2004). In addition, we developed recovery test of microdialysis cannula by inserting the probes into a test solution containing external known concentrations of monoamines, AD or ACh under controlled perfusion of respective mobile phase. Dialysates were collected in a triplicate fashion under these experimental conditions. Each sample collected from *in vitro* recovery study was analyzed and the peak area ratio for monoamines, AD or ACh was calculated against the known standards. For obtaining the recovery rate, data were calculated by using the formulae: recovery rate (%) = (the peak area ratio of the sample from microdialysis sample)/(the peak area ratio of the sample in the test solution). The whole recovery *in vitro* for calibration of microdialysis probes procedure was carried out as previous reports (Porkka-Heiskanen et al., 2000; Murillo-Rodríguez et al., 2004; Blanco-Centurión et al., 2006).

**Histological Verification of Probe Location in Microdialysis Experiments**

After all microdialysis experiments, rats were sacrificed with a lethal dose of pentobarbital for the standard procedure for vascular perfusion (saline solution [0.9%] followed by formaldehyde [4%]). Next, the brain was removed and post-fixed overnight in formaldehyde (4%) followed by 10, 20, and 30% sucrose/0.1 M PBS during 24 h (each concentration). At last, all brains were cut in coronal sections (20 µm) using a Portable Bench-top Cryostat (Leica CM1100, Wetzlar, Germany) and collected in 1:5 serial order. One serial was used for probe location and it was identified by plotting using rat brain atlas (Paxinos and Watson, 2005). All histological procedures were developed as previously reported (Murillo-Rodríguez et al., 2004; Blanco-Centurión et al., 2006).

**Statistical Analysis**

As described in Experiment 2.

**RESULTS**

**Effects on Sleep After Injections of DZNep or GSK-J1 During the Lights-On or the Lights-Off Period**

In the first experiment, DZNep treatment (0.1, 1.0, or 10 mg/kg, i.p.) given at the beginning of the lights-on period caused a dose-dependent increase of W (*Figure 1A*; *P* < 0.0001) as well as a decrease in SWS (*Figure 1B*; *P* < 0.0001) and REMS (*Figure 1C*; *P* < 0.0001). Post hoc analysis test showed significant differences between experimental groups for W, SWS, and REMS (*P* < 0.0001). No statistical changes were observed in total W (*Figure 1D; P* > 0.9), SWS (*Figure 1E; P > 0.6), or REMS (*Figure 1F; *P* > 0.5) if drug was administered at the beginning of the lights-off period. From data obtained, we conclude that waking was enhanced by inhibiting methylase using DZNep if administered during the lights-on period.

When GSK-J1 was injected (0.1, 1.0, or 10 mg/kg, i.p.) at the beginning of the lights-on period, no statistical effects were observed in total time of W (*Figure 2A; P > 0.3), SWS (*Figure 2B; *P > 0.6*), or REMS (*Figure 2C; *P > 0.4*). However, if administered at the beginning of the lights-off period, the inhibitor of histone demethylase decreased alertness (*Figure 2D; P < 0.0001*), enhanced SWS (*Figure 2E; P < 0.0001*) and decreased REMS (*Figure 2F; *P < 0.0003*). Further post hoc analysis test demonstrated significant differences between experimental trials in W, SWS, and REMS (*P < 0.0001*). We conclude that inhibition of histone demethylase promoted sleep-inducing effect when injected during the lights-off period.

**Effects on Sleep Parameters After Administrations of DZNep or GSK-K1 During the Lights-On or the Lights-Off Period**

The sleep parameters (Table 1), including the frequency (number of bouts), mean duration (min) and latency (min) of W, SWS, and REMS were analyzed after pharmacological trials following previous procedures (Murillo-Rodríguez et al., 2017). In this regard, administration of DZNep during the lights-on period induced no changes in the number of bouts of waking (*P > 0.1*), whereas SWS (*P < 0.002*) and REMS were decreased (*P < 0.003*). Scheffé’s post hoc test showed significant differences between experimental groups for SWS and REMS (*P < 0.01*). In addition, mean duration displayed statistical enhancements in W (*P < 0.04*), with no changes in SWS (*P > 0.3*) but REMS was found increased (*P < 0.0001*). The Scheffé’s post hoc test showed us inter-group differences in W and REMS (*P < 0.01*). Lastly, latency for SWS (*P > 0.3*) and REMS (*P > 0.3*) displayed no statistical changes in rats that received DZNep.

The analysis of sleep parameters (Table 2) after injection of DZNep during the lights-off period showed no statistical differences among experimental trials in frequency of waking
FIGURE 1 | Effects on total time (4 h of sleep recordings) of wakefulness (W), slow wave sleep (SWS), and rapid eye movement sleep (REMS) after injection of vehicle (CTL \( n = 5 \)) or DZNep (0.1, 1.0, or 10 mg/kg, i.p.; each dose, \( n = 5 \)) during either lights-on or lights-off period. Effects were observed in W, SWS, or REMS when DZNep was injected during the lights-on period (A–C, respectively; * vs. Control; † vs. DZNep-0.1, ‡ vs. DZNep-1.0; \( P < 0.05 \)). However, when administered at the lights-off period, no changes in sleep stages were found (D–F, respectively).

GSK-J1 caused no statistical differences (Table 3) once injected during the lights-on period in the frequency of waking (\( P > 0.7 \)) but decreased the number of bouts in SWS (\( P < 0.0001 \)) and REMS (\( P < 0.05 \)). The Scheffé’s post hoc test showed

\( P > 0.5 \), SWS (\( P > 0.3 \)) and REMS (\( P > 0.2 \)). Mean duration for W, SWS, and REMS showed no significant changes as well (\( P > 0.6 \), \( P > 0.5 \), and \( P > 0.9 \), respectively). Alike results were observed in latency for SWS (\( P > 0.4 \)) and REMS (\( P > 0.4 \)).
inter-group differences in SWS and REMS ($P < 0.005$). Mean
duration showed no statistical differences in W ($P > 0.1$), SWS
($P > 0.1$), or REMS ($P > 0.7$). Similar findings were observed in
latency for SWS ($P > 0.1$) and REMS ($P > 0.2$).

Table 4 shows the sleep parameters in GSK-J1-treated
rats across lights-off period. As demonstrated, no statistical
differences were found in frequency for W ($P > 0.2$) while a
significant decrease was observed in SWS ($P < 0.03$) as well
as REMS ($P < 0.04$). The Scheffé’s post hoc test displayed
differences for SWS ($P < 0.008$) and REMS ($P < 0.05$). Mean
duration showed no statistical changes in alertness ($P > 0.5$)
whereas a significant increase was found in SWS ($P < 0.01$)
and REMS ($P < 0.005$). The Scheffé’s post hoc test showed
differences for SWS ($P < 0.009$) and REMS ($P < 0.01$).
Finally, latency was found with no significant changes for
SWS ($P > 0.1$) but REMS displayed a significant diminution

![Figure 2](image-url)
TABLE 2 | Effects on sleep parameters (frequency, mean duration, and latency) after the administration of vehicle (CTL $n = 5$) or DZNep (0.1, 1.0, or 10 mg/kg, i.p.; each dose, $n = 5$) during lights-on period * vs. Control; # vs. DZNep-0.1, % vs. DZNep-1.0; $P < 0.05$).

| Wakefulness | Frequency (number of bouts) $\left( F_{(3, 16)} = 1.849, P = 0.1 \right)$ | Mean duration (min) $\left( F_{(3, 16)} = 3.484, P < 0.04 \right)$ | Latency (min) |
|-------------|---------------------------------|---------------------------------|-------------|
| CTL         | 19.72 ± 1.0                     | 1.70 ± 0.2                     | 0.0 ± 0.0   |
| DZNep-0.1   | 19.48 ± 1.1                     | 1.80 ± 0.1                     | 0.0 ± 0.0   |
| DZNep-1.0   | 24.72 ± 3.6                     | 3.44 ± 1.1                     | 0.0 ± 0.0   |
| DZNep-10    | 16.40 ± 3.1                     | 4.69 ± 0.9*<sup>###</sup> | 0.0 ± 0.0   |

| Slow wave sleep | Frequency (number of bouts) $\left( F_{(3, 16)} = 7.804, P < 0.002 \right)$ | Mean duration (min) $\left( F_{(3, 16)} = 1.168, P = 0.3 \right)$ | Latency (min) $\left( F_{(3, 16)} = 1.310, P = 0.3 \right)$ |
|-----------------|---------------------------------|---------------------------------|-------------|
| CTL             | 38.80 ± 1.9                     | 2.96 ± 0.1                     | 26.28 ± 4.0 |
| DZNep-0.1       | 38.08 ± 1.4                     | 3.01 ± 0.2                     | 28.99 ± 4.0 |
| DZNep-1.0       | 37.86 ± 3.8                     | 4.48 ± 1.9                     | 35.28 ± 3.7 |
| DZNep-10        | 23.72 ± 3.0*<sup>###</sup> | 5.32 ± 0.7                     | 25.52 ± 4.2 |

| REMS | Frequency (number of bouts) $\left( F_{(3, 16)} = 7.092, P < 0.003 \right)$ | Mean duration (min) $\left( F_{(3, 16)} = 13.946, P < 0.0001 \right)$ | Latency (min) $\left( F_{(3, 16)} = 1.02, P = 0.3 \right)$ |
|------|---------------------------------|---------------------------------|-------------|
| CTL  | 19.52 ± 2.3                     | 0.80 ± 0.1                      | 55.32 ± 12.8|
| DZNep-0.1 | 19.12 ± 2.3                     | 0.80 ± 0.1                      | 50.58 ± 12.8|
| DZNep-1.0 | 12.0 ± 1.3                     | 1.04 ± 0.3                     | 49.72 ± 7.8 |
| DZNep-10 | 10.00 ± 0.8*<sup>###</sup> | 2.50 ± 0.2*<sup>###</sup> | 32.88 ± 4.0 |

Effects on Sleep Power Spectra After Treatments of DZNep or GSK-J1 During the Lights-On or the Lights-Off Period

Systemic injection of DZNep during lights-on enhanced alpha (Figure 3A; $P < 0.0001$) as well as a decrease in delta (Figure 3B; $P < 0.0001$) and theta power spectra (Figure 3C; $P < 0.0001$). The Scheffé’s post hoc test showed inter-group differences for alpha ($P < 0.0001$), delta ($P < 0.001$), and theta power spectra ($P < 0.0001$). No significant changes were found in power spectra analysis for alpha (Figure 3D; $P > 0.6$), delta (Figure 3E; $P > 0.6$) or theta (Figure 3F; $P > 0.5$) during the lights-off period in DZNep-treated rats.

Next, we evaluated whether GSK-J1 would induce effects in power spectra if injected during the lights-on or the lights-off phase. Results showed that when administered at the beginning of the lights-on period no statistical changes in
**TABLE 3** | Effects on sleep parameters (frequency, mean duration, and latency) after the treatment of vehicle (CTL [n = 5]) or DZNep (0.1, 1.0, or 10 mg/kg, i.p.; each dose, n = 5) during lights-off period (* vs. Control; # vs. DZNep-0.1, % vs. DZNep-1.0; P < 0.05).

| Wakefulness | Frequency (number of bouts) | Mean duration (min) | Latency (min) |
|-------------|-----------------------------|---------------------|---------------|
| *Control*   | 19.72 ± 1.0                 | 1.70 ± 0.2          | 0.0 ± 0.0     |
| GSK-0.1     | 21.62 ± 1.1                 | 1.71 ± 0.3          | 0.0 ± 0.0     |
| GSK-1.0     | 21.46 ± 3.7                 | 3.62 ± 1.1          | 0.0 ± 0.0     |
| GSK-10      | 23.14 ± 1.5                 | 2.59 ± 0.1          | 0.0 ± 0.0     |

| Slow wave sleep | Frequency (number of bouts) | Mean duration (min) | Latency (min) |
|-----------------|-----------------------------|---------------------|---------------|
| *Control*       | 38.80 ± 1.9                 | 2.96 ± 0.1          | 26.28 ± 4.0   |
| GSK-0.1         | 37.86 ± 3.0                 | 2.36 ± 0.2          | 21.60 ± 4.6   |
| GSK-1.0         | 26.78 ± 3.5*<sup>-A</sup>  | 7.60 ± 3.7          | 37.60 ± 9.9   |
| GSK-10          | 13.44 ± 1.0*<sup>-A,B</sup> | 8.65 ± 1.8         | 18.08 ± 5.0   |

| REMS            | Frequency (number of bouts) | Mean duration (min) | Latency (min) |
|-----------------|-----------------------------|---------------------|---------------|
| *Control*       | 19.52 ± 2.3                 | 0.80 ± 0.1          | 55.32 ± 12.8  |
| GSK-0.1         | 20.80 ± 3.2                 | 0.76 ± 0.04         | 36.92 ± 6.7   |
| GSK-1.0         | 15.40 ± 2.9                 | 0.75 ± 0.07         | 51.88 ± 13.9  |
| GSK-10          | 10.20 ± 1.9*<sup>-A</sup>  | 1.17 ± 0.5          | 27.56 ± 6.9   |

**TABLE 4** | Effects on sleep parameters (frequency, mean duration, and latency) after the application of vehicle (CTL [n = 5]) or GSK-J1 (0.1, 1.0, or 10 mg/kg, i.p.; each dose, n = 5) during lights-off period (* vs. Control; # vs. GSJ-0.1, % vs. GSK-1.0; P < 0.05).

| Wakefulness | Frequency (number of bouts) | Mean duration (min) | Latency (min) |
|-------------|-----------------------------|---------------------|---------------|
| *Control*   | 17.70 ± 1.8                 | 5.15 ± 2.9          | 0.0 ± 0.0     |
| GSK-0.1     | 22.76 ± 3.0                 | 5.05 ± 1.6          | 0.0 ± 0.0     |
| GSK-1.0     | 27.70 ± 5.8                 | 3.03 ± 1.3          | 0.0 ± 0.0     |
| GSK-10      | 28.014 ± 3.2                | 1.81 ± 0.1          | 0.0 ± 0.0     |

| Slow wave sleep | Frequency (number of bouts) | Mean duration (min) | Latency (min) |
|-----------------|-----------------------------|---------------------|---------------|
| *Control*       | 37.50 ± 1.9                 | 2.38 ± 0.2          | 28.40 ± 12.3  |
| GSK-0.1         | 34.22 ± 4.3                 | 2.38 ± 0.2          | 45.04 ± 6.1   |
| GSK-1.0         | 26.52 ± 7.7*<sup>-B</sup>  | 12.72 ± 4.4*<sup>-B</sup> | 27.00 ± 8.4  |
| GSK-10          | 17.74 ± 1.9*<sup>-B</sup>  | 9.40 ± 2.2*<sup>-B</sup> | 13.88 ± 3.0*<sup>-B</sup> |

| REMS            | Frequency (number of bouts) | Mean duration (min) | Latency (min) |
|-----------------|-----------------------------|---------------------|---------------|
| *Control*       | 22.68 ± 1.5                 | 0.88 ± 0.08         | 56.80 ± 12.9  |
| GSK-0.1         | 12.00 ± 2.8*<sup>-B</sup>  | 0.63 ± 0.1          | 56.96 ± 6.9   |
| GSK-1.0         | 11.20 ± 1.8*<sup>-B</sup>  | 0.50 ± 0.08*<sup>-B</sup> | 34.80 ± 8.9  |
| GSK-10          | 12.60 ± 2.0*<sup>-B</sup>  | 1.05 ± 0.1*<sup>-B</sup> | 18.60 ± 3.5*<sup>-B</sup> |

alpha (Figure 4A; P > 0.6), delta (Figure 4B; P > 0.6), or theta power spectra (Figure 4C; P > 0.6) were observed. Although if given at the beginning of the lights-off period, the histone demethylation inhibitor diminished alpha (Figure 4D; P < 0.0001), but increased SWS (Figure 4E; P < 0.0001) and reduced theta power spectra (Figure 4F; P < 0.0001). The Scheffé’s post hoc test showed inter-group differences for alpha (P < 0.0001), delta (P < 0.0001), and theta power spectra (P < 0.0001).

**Effects on the Extracellular Levels of Monoamines, Adenosine, and Acetylcholine After Administrations of DZNep or GSK-J1**

The localization of the microdialysis probe in the AcbC or basal forebrain is shown in Figure 5. The schematic illustration of the position of the probe into AcbC (Figure 5A) or basal forebrain (Figure 5B) is displayed whereas microphotographies...
FIGURE 3 | Effects on alpha (during W), delta (across SWS), and theta power spectra (during REMS) after injection of vehicle (CTL [n = 5]) or DZNep (0.1, 1.0, or 10 mg/kg, i.p.; each dose, n = 5) during either lights-on or lights-off period. Effects were observed in alpha, delta and theta power spectra when DZNep was injected during the lights-on period (A–C, respectively; * vs. Control; # vs. DZNep-0.1, % vs. DZNep-1.0; P < 0.05). However, when administered at the lights-off period, no changes in power spectra were found (D–F, respectively).

from localization of microdialysis cannulae track into AChC and basal forebrain is also shown (Figures 5C,D, respectively).

Since statistical changes in DZNep-treated rats were observed in sleep studies during the lights-on period (see section “Results”), our next aim was to determine whether administrations of this compound would promote neurochemical changes if injected only at the beginning of the lights-on period. Having this aim in mind, we injected DZNep (0.1, 1.0, or 10 mg/kg, i.p.) to rats and collected samples from microdialysis probes during the lights-on phase. Injection of compound caused a dose-dependent enhancement in extracellular contents of DA (Figure 6A; P < 0.0001), NE (Figure 6B; P < 0.0001), EP (Figure 6C; P < 0.0001), 5-HT (Figure 6D; P < 0.0001), AD (Figure 6E; P < 0.0001), and
Effects on alpha (during W), delta (across SWS), and theta power spectra (during REMS) after administration of vehicle (CTL \( n = 5 \)) or GSK-J1 (0.1, 1.0, or 10 mg/kg, i.p.; each dose, \( n = 5 \)) during either lights-on or lights-off period. When administered at the lights-on period, GSK-J1 caused no statistical changes in alpha, delta or theta power spectra (\( A-C \), respectively). However, if injected during the lights-off period, GSK-J1 decreased alpha but decreased delta and diminished theta power spectra (\( D-F \), respectively; * vs. Control; # vs. GSK-0.1, % vs. GSK-1.0; \( P < 0.05 \)).

ACh (Figure 6F; \( P < 0.0001 \)). The Scheffé's post hoc test showed inter-group significant differences for DA (\( P < 0.0001 \)), NE (\( P < 0.0001 \)), EP (\( P < 0.0001 \)), 5-HT (\( P < 0.0001 \)), AD (\( P < 0.0001 \)), and ACh (\( P < 0.03 \)). We conclude that DZNep was able to increase several sleep-related neurochemicals when injected during the lights-on period.

In the following experiment, we evaluated if GSK-J1 would be able to provoke effects in extracellular levels of DA, NE, EP, 5-HT, AD, and ACh. Due that GSK-J1 exerted influence on sleep during the lights-off period, we administered this compound (0.1, 1.0, or 10 mg/kg, i.p.) at the beginning of the dark period. A decrease in a dose-dependent fashion of the contents of DA (Figure 7A;
**FIGURE 5** Localization of the microdialysis probe in the microdialysis experiments. (A,B) Shows the schematic illustration from the rat brain atlas (Paxinos and Watson, 2005) with the location of the microdialysis probe in AcbC (coordinates: A = +1.2, L = +2.0, and H = −7.0 mm, with reference to Bregma [Paxinos and Watson, 2005]) or basal forebrain (coordinates: A = −0.35; L = 2.0; and H = −7.5 mm, with reference to Bregma [Paxinos and Watson, 2005]), respectively. Microphotographies show the microdialysis probe track in AcbC or basal forebral in (C,D), respectively. Abbreviations were taken from the Paxinos and Watson (2005): AcbC, nucleus accumbens; LPO, lateral preoptic area. Scale bar: 100 μm.

**DISCUSSION**

Histone methylation/demethylation activity has been studied in several biomedical aspects, with emphasis in cancer (Kunts et al., 2017; Pérez et al., 2018; Porcellini et al., 2018; Tong et al., 2018; Wijenayake et al., 2018). Despite significant advances have been achieved by studying the molecular role of histones in regulating health conditions, no direct evidence was available regarding the influence of histone methylation/demethylation activity on neurobiological phenomena such as the sleep-wake cycle and sleep-related neurochemicals. Here, we described that histone methylation inhibition by DZNep enhanced waking if injected during the lights-on period whereas histone demethylation inhibition by GSK-J1 caused a sleep-inducing effect if administered during the lights-off period. Further effects were observed in DZNep-treated rats in sleep parameters during the lights-on period. In conclusion, GSK-J1 diminished the levels of neurochemicals if administered during the lights-off period.

Histone methylation/demethylation activity has been studied in several biomedical aspects, with emphasis in cancer (Kunts et al., 2017; Pérez et al., 2018; Porcellini et al., 2018; Tong et al., 2018; Wijenayake et al., 2018). Despite significant advances have been achieved by studying the molecular role of histones in regulating health conditions, no direct evidence was available regarding the influence of histone methylation/demethylation activity on neurobiological phenomena such as the sleep-wake cycle and sleep-related neurochemicals. Here, we described
Effects observed after the administration of the drugs during the light or dark phase suggest a possible sensitivity of the availability of histone methylation or demethylation depending on the phase of the light–dark cycle. This possible sensitivity could be the cause of the effects observed in sleep and neurochemical levels.
FIGURE 7 | Effects on extracellular levels of dopamine, norepinephrine, epinephrine, 5-HT, adenosine, and acetylcholine (4 h of sampling) after the administration of vehicle (CTL, n = 5) or GSK-J1 (0.1, 1.0, or 10 mg/kg, i.p.; each dose, n = 5) during the lights-off period. The levels of dopamine, norepinephrine, epinephrine, 5-HT, adenosine, and acetylcholine were found decreased after pharmacological trials (A–F, respectively; * vs. Control; # vs. GSK-0.1, % vs. GSK-1.0; P < 0.05).

Although current findings provide novel insights of the likely role of inhibition of either histone methylation or histone demethylation on sleep and neurochemicals modulation, several limitations in the current study have been identified. For example, it is difficult to determine whether the changes observed in sleep may be cause or effect on the variations found in the neurochemicals analyzed. Moreover, previous reports have indicated that DZNep globally inhibits histone methylation acting as a non-selective molecular drug (Miranda et al., 2009). Thus, experiments testing the effects on sleep by using selective
functions and histone activity, it is conceivable that perhaps those changes in neurotransmission (Sun et al., 2013; Lamadema et al., 2019; Ricketts et al., 2019), including those that have been associated with sleep control (Wang and Liu, 2015; Curry et al., 2018). It would be interesting to determine whether using DZNep may control sleepiness in patients with cancer or if GSK-J1 might modulate insomnia caused by stress prior to undergoing radiotherapy (Davies et al., 2017; Vin-Raviv et al., 2017; Miladinia et al., 2018; Zhou et al., 2018). Testing this hypothesis in experimental models of sleep disturbances would give us an important comprehensive insight of the role of histone methylation/demethylation in the management of sleep disturbances. Moreover, circadian fluctuations of histone methylation/demethylation activity would provide us foundations for in which time becomes a critical variable to obtain the desirable effects. Thus, chronopharmacological studies would embrace endogenous periodicities and biological timing of the activity of histones to ensure that drugs are acting on time coupled with these rhythmicities and, then enhance the expected effects.

Although limited evidence is available in regards the role of histone methylation/demethylation activity in neurobiological phenomena, our studies extend these data to suggest that nuclear elements could induce sleep and neurochemical modulation (Duan et al., 2016; Gaine et al., 2018; Morales-Lara et al., 2018; Shalaby et al., 2018). Following this idea, we have developed a conceptual framework that suggests that manipulation of histone methylation/demethylation activity could engage sleep-related genes: chromatin organization by histone methylation/demethylation, implies the modulation of the activity of large numbers of genes (MacPherson et al., 2018; Lamadema et al., 2019; Ricketts et al., 2019), including those that have been associated with sleep control (Wang and Liu, 2016; Tomita et al., 2017; Kim et al., 2018). However, the role of histone methylation/demethylation in sleep remains poorly understood. Therefore, this is the first direct evidence that drugs aimed to inhibit histone methylation or demethylation are related with sleep and neurochemicals effects. In addition, the importance of DNA-methylation and demethylation in neurotransmission has been partially studied. Despite that several studies have reported the link between methylation or demethylation effects on several neurobiological processes, such as learning and memory as well as pathological conditions, it is difficult to draw solid conclusions about how the histone methylation and demethylation inhibition may exert influence on the neurotransmitter contents. The available data regarding the modifications of histones in conjunction with behavior, implicitly suggest changes in neurotransmission (Sun et al., 2013; Cholewa-Waclaw et al., 2016; Bayraktar and Kreutz, 2018). With respect to those results seen with relationship between behavioral functions and histone activity, it is conceivable that perhaps those effects could be attributable to neurotransmitters alterations. However, it remains to be described if histone methylation and demethylation inhibition induce changes in neurotransmitters by engaging enzymatic process involved in the formation of DA, NE, EP, 5-HT, AD, and ACh. It cannot be rule out that enzymatic component in the metabolic pathway of studied neurotransmitters could be inhibited by the methylation or demethylation inhibition. Importantly, the DNA methylation and histone acetylation have been implicated in the modulation of synaptic transmission of several neurotransmitters, including key genes in the GABAergic pathway (Nelson and Monteggia, 2011; Holloway and González-Maeso, 2015; Shrestha and Offer, 2016). Indeed, complementary experiments testing the role of methylation and demethylation inhibition on the biosynthesis of DA, NE, EP, 5-HT, AD, and ACh are needed to provide better understanding of the phenomena. Further studies will be required to determine the specific mechanism of action of DZNep or GSK-J1 on sleep and neurochemical modulation. We assume that in the near future, additional studies might describe the histone methylation or demethylation profiles as molecular markers for diagnostics of sleep disturbances or the application of drugs such as DZNep or GSK-J1 at specific time of the circadian rhythm as therapeutic strategy. Taken together, our findings demonstrate that histone methylation inhibition promotes waking whereas sleep is promoted when histone demethylation is suppressed.

DATA AVAILABILITY

The datasets generated for this study are available on request to the corresponding author.

AUTHOR CONTRIBUTIONS

EM-R designed and implemented experiments, analyzed the data, assembled the figures, and edited the manuscript. GA-S contributed with technical EEG/EMG surgical support. JAB helped with revision of experimental designs. TY provided statistical analysis guidance. SM contributed with revision of literature and experimental designs. HB provided guidance with writing the manuscript. DT-C revised data and supported assembling the figures. DM contributed editing statistical data. LC contributed revising data and editing the manuscript. ABV contributed editing and analyzing data. All authors revised all data set and approved the final version of the manuscript.

FUNDING

This work was supported by The University of California Institute for Mexico and the United States (UC MEXUS) and Consejo Nacional de Ciencia y Tecnología (CONACYT; Grant# CN-17-19) and Escuela de Medicina, Universidad Anáhuac Mayab (Grant: PresInvEMR2017) given to EM-R.

Murillo-Rodríguez et al.

Histone Methylation/Demethylation Inhibition Modulates Sleep
REFERENCES

Almeida, L. O., Neto, M. P. C., Sousa, L. O., Tannous, M. A., Curti, C., and Leopoldino, A. M. (2017). SET oncoprotein accumulation regulates transcription through DNA demethylation and histone hypoacetylation. Oncotarget 8, 26802–26818. doi: 10.18632/oncotarget.15818
Amélie, C., Pedersen, N. P., Ferrari, L. L., Venner, A., Bass, C. E., Arrigoni, E., et al. (2015). Basal forebrain control of wakefulness and cortical rhythms. Nat. Commun. 6, 8744. doi: 10.1038/ncomms9744
Bauer, A. J., and Martin, K. A. (2017). Coordinating regulation of gene expression in cardiovascular disease: interactions between chromatin modifiers and transcription factors. Front. Cardiovasc. Med. 4. doi: 10.3389/fcvm.2017.00019
Bayraktar, G., and Kreutz, M. R. (2018). The role of activity-dependent DNA demethylation in the adult brain and in neurological disorders. Front. Mol. Neurosci. 11:169. doi: 10.3389/fnmol.2018.00169
Blanco-Centurión, C., Xu, M., Murillo-Rodríguez, E., Gerashchenko, D., Shiromani, A. M., Salin-Pascual, R. J., et al. (2006). Adenosine and sleep homeostasis in the basal forebrain. J. Neurosci. 31, 8092–8100. doi: 10.1523/JNEUROSCI.2181-06.2006
Boehm, D., and Ott, M. (2017). Host methyltransferases and demethylases: potential new epigenetic targets for HIV cure strategies and beyond. AIDS Res. Hum. Retroviruses 33, S8–S22. doi: 10.1089/aid.2017.0180
Castillo, R. M., Squarize, C. H., and Almeida, L. O. (2017). Epigenetic modifications and head and neck cancer: implications for tumor progression and resistance to therapy. Int. J. Mol. Sci. 18:1506. doi: 10.3390/ijms18071506
Choi, S. I., Jung, S. W., Huh, S., Chung, Y. S., Cho, H., Kang, H., et al. (2017). Alteration of DNA methylation in gastric cancer with chemotherapy. J. Microbiol. Biotechnol. 27, 1367–1378. doi: 10.4014/jmb.1704.04035
Cholewa-Waclaw, J., Bird, A., von Schimmelmann, M., Schaefer, A., Yu, H., Song, H., et al. (2016). The role of epigenetic mechanisms in the regulation of gene expression in the nervous system. J. Neurosci. 36, 11427–11434. doi: 10.1523/JNEUROSCI.2492-16.2016
Curry, E., Zeller, C., Masrour, N., Patten, D. K., Gallon, J., Wilhelm-Benartzi, D., Boehm, D., and Ott, M. (2017). Host methyltransferases and demethylases: potential new epigenetic targets for HIV cure strategies and beyond. AIDS Res. Hum. Retroviruses 33, S8–S22. doi: 10.1089/aid.2017.0180
Davies, A. N., Patel, S. D., Gregory, A., and Lee, B. (2017). Observational study of acquired resistance to chemotherapy are identified in ovarian tumors by targeting histone methylation in cancer. J. Neurosci. 291, 297–303. doi: 10.1016/j.neuroscience.2014.04.006
Grupe, M., Paolone, G., Jensen, A. A., Sandager-Nielsen, K., Sarter, M., and Johanssen, C., Velupillai, S., Tumber, A., Szykowska, A., Hookway, E. S., Nowak, R. P., et al. (2016). Structural analysis of human KDM5B guides histone demethylation inhibitor development. Nat. Chem. Biol. 12, 539–545. doi: 10.1038/nchembio.2087
Kaluski, S., Portillo, M., Besnard, A., Stein, D., Einav, M., Zhong, L., et al. (2017). Neuroprotective functions for the histone deacetylase SIRT6. Cell. Rep. 18, 3052–3062. doi: 10.1016/j.celrep.2017.03.008
Kaniskan, H. Ü., Martini, M. L., and Jin, J. (2018). Inhibitors of protein methyltransferases and demethylases. Chem. Rev. 118, 989–1068. doi: 10.1021/acs.chemrev.6b00801
Khan, N. M., and Haqqi, T. M. (2018). Epigenetics in osteoarthritis: potential of HDAC inhibitors as therapeutics. Pharmacol. Res. 128, 73–79. doi: 10.1016/j.phrs.2017.08.007
Kim, M., de la Peña, J. B., Cheong, J. H., and Kim, H. J. (2018). Neurobiological functions of the period circadian clock 2 gene, Per2. Biomed. Ther. 26, 358–367. doi: 10.4062/biomolther.2017.131
Kunts, T. A., Mikhailova, E. S., Marinink, I. O., Varaksin, N. A., Autshulys, A. I., and Lyakhovich, V. V. (2017). Cytokine production by the tumor from patients with breast cancer in different age groups. Dokl. Biol. Sci. 475, 172–174. doi: 10.1134/S0012496617040020
Kuntz, K. W., Campbell, J. E., Keilhack, H., Pollock, R. M., Knutson, S. K., Porter-Scott, M., et al. (2016). The importance of being ME: magic methyls, histone methyltransferases inhibitors, and the discovery of tazemetostat. J. Med. Chem. 59, 1556–1564. doi: 10.1021/acs.jmedchem.5b01501
Larvandema, N., Burr, S., and Brewer, A. C. (2019). Dynamic regulation of epigenetic demethylation by oxygen availability and cellular redox. Free Radic. Biol. Med. 131, 282–298. doi: 10.1016/j.freeradbiomed.2018.12.009
Li, L., Zhang, Y., Xu, M., Rong, R., Wang, J., Zhu, T., et al. (2016). Inhibition of histone methyltransferase EZH2 ameliorates early acute renal allograft rejection in rats. BMC Immunol. 17:41. doi: 10.1186/s12865-016-0179-3
MacPherson, Q., Beltran, B., and Spakowitz, A. J. (2018). Bottom-up modeling of chromatin segregation due to epigenetic modifications. Proc. Natl. Acad. Sci. U.S.A. 115, 12729–12744. doi: 10.1073/pnas.1812268115
McCabe, M. T., Mohammad, H. P., Barbash, O., and Kruger, R. G. (2017). Targeting histone methylation in cancer. Cancer J. 23, 292–301. doi: 10.1097/PPO.0000000000000283
Mijangos-Moreno, S., Poot-Aké, A., Arankowsky-Sandoval, G., and Murillo-Rodríguez, E. (2014). Intrahepaticalbumic injection of cannabinoid increases the extracellular levels of adenosine in nucleus accumbens in rats. Neurosci. Res. 84, 60–63. doi: 10.1016/j.neures.2014.04.006
Mijangos-Moreno, S., Poot-Aké, A., Guzmán, K., Arankowsky-Sandoval, G., Arias-Carrion, O., Zaldívar-Rae, J., et al. (2016). Sleep and neurochemical modulation by the nuclear peroxisome proliferator-activated receptor α (PPAR-α) in rats. Neurosci. Res. 105, 65–69. doi: 10.1016/j.neures.2015.09.005
Miladínia, M., Baraz, S., Ramezani, M., and Malehi, A. S. (2018). The relationship between pain, fatigue, sleep disorders and quality of life in adult patients with acute leukaemia: during the first year after diagnosis. Eur. J. Cancer Care 27:e12762. doi: 10.1111/ecc.12762
Miranda, T. B., Cortez, C. C., Yoo, C. B., Liang, G., Abe, M., Kelly, T. K., et al. (2009). DZNep is global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther. 8, 1579–1588. doi: 10.1158/1535-7163.MCT-09-0013
Morales-Lara, D., De-la-Peña, C., and Murillo-Rodríguez, E. (2018). Dad’s snoring may have left molecular scars in your DNA: the emerging role of epigenetics in sleep disorders. Mol. Neurobiol. 55, 2731–2724. doi: 10.1007/s12037-018-0409-6
Murillo-Rodríguez, E., Arankowsky-Sandoval, G., Barbosa Rocha, N., Peniche-Amante, R., Barcila Veras, A., Machado, S., et al. (2018). Systemic injections of cannabinoid enhance acetylcholine levels from basal forebrain in rats. Neurosci. Res. 43, 1511–1518. doi: 10.1016/j.neures.2018.06.007
Murillo-Rodríguez, E., Blanco-Centurión, C., Gerashchenko, D., Salin-Pascual, R. J., and Shiromani, P. J. (2014). The diurnal rhythm of adenosine levels in the basal forebrain of young and old rats. Neuroscience 123, 361–370.
Pasculli, B., Barbano, R., and Parrella, P. (2018). Epigenetics of breast cancer: biology and clinical implication in the era of precision medicine. *Semin. Cancer Biol.* 51, 22–35. doi: 10.1016/j.semcancer.2018.01.007

Paxinos, G., and Watson, C. (2005). *The Rat Brain in Stereotaxic Coordinates*. San Diego, CA: Academic Press.

Pérez, R. F., Tejedor, J. R., Bayón, G. F., Fernández, A. F., and Fraga, M. F. (2018). Distinct chromatin signatures of DNA hypomethylation in aging and cancer. *Aging Cell* 17:e12744. doi: 10.1111/ager.12744

Peyer, L., and Greil, R. (2015). Digging deep into ‘dirty’ drugs - modulation of the methylation machinery. *Drug Metab. Rev.* 47, 252–279. doi: 10.3109/03602532.2014.995379

Porcellini, E., Laprovitera, N., Riefo, M., Ravaoli, M., Garajova, I., and Ferracin, M. (2018). Epigenetic and epitranscriptomic changes in colorectal cancer: diagnostic, prognostic, and treatment implications. *Cancer Lett.* 419, 84–95. doi: 10.1016/j.canlet.2018.01.049

Porkka-Heiskanen, T., Strecker, R. E., and McCarley, R. W. (2000). Brain site-specificity of extracellular adenosine concentration changes during sleep deprivation and spontaneous sleep: an in vivo microdialysis study. *Neuroscience* 99, 507–517.

Qiu, M. H., Liu, W., Qu, W. M., Urade, Y., Lu, J., and Huang, Z. L. (2012). The role of nucleus accumbens core/shell in sleep-regulation and their involvement in modafinil-induced arousal. *PLoS One* 7:e45471. doi: 10.1371/journal.pone.0045471

Ricketts, M. D., Han, J., Szurgot, M. R., and Marmorstein, R. (2019). Molecular basis for chromatin assembly and modification by multiprotein complexes. *Protein Sci.* 28, 329–343. doi: 10.1002/pro.3535

Shalaby, N. A., Pinzon, J. H., Narayanan, A. S., Jin, E. J., Ritz, M. P., Dove, R. J., et al. (2018). ImPc domain proteins modulate circadian behaviors and sleep in Drosophila. *Sci. Rep.* 8:815. doi: 10.1038/s41598-017-18989-1

Shrestha, S., and Offer, S. M. (2016). Epigenetic regulations of GABAergic neurotransmission: relevance for neurological disorders and epigenetic therapy. *Med. Hypotheses* 4, 1–19.

Sun, H., Kennedy, P. J., and Nestler, E. J. (2013). Epigenetics of the depressed brain: role of histone acetylation and methylation. *Neuropsychopharmacology* 38, 124–137. doi: 10.1038/npp.2012.73

Thomas, E. A., and D’Mello, S. R. (2018). Complex neuroprotective and neurotoxic effects of histone deacetylases. *J. Neurochem.* 145, 96–110. doi: 10.1111/jnc.14309

Tomita, J., Ban, G., and Kume, K. (2017). Genes and neural circuits for sleep of the fruit fly. *Neurosci. Res.* 118, 82–91. doi: 10.1016/j.neures.2017.04.010

Tong, Y., Li, Y., Gu, H., Wang, C., Liu, F., Shao, Y., et al. (2018). Distinct chromatin signatures of DNA hypomethylation in aging and cancer. *Aging Cell* 17:e12744. doi: 10.1111/ager.12744

Vanini, G., Lydic, R., and Baghdoyan, H. A. (2012). GABA-to-ACh ratio in basal forebrain and cerebral cortex varies significantly during sleep. *Sleep* 35, 1325–1334. doi: 10.5666/sleep.2106

Vin-Raviv, N., Akinyemiju, T. F., Galea, S., and Bobvbjerg, D. H. (2017). Sleep disorder diagnoses and clinical outcomes among hospitalized breast cancer patients: a nationwide inpatient sample study. *Support. Care Cancer* 26, 1833–1840. doi: 10.1007/s00520-017-4012-1

Wang, Z. J., and Liu, J. F. (2016). The molecular basis of insomnia: implication for therapeutic approaches. *Drug Dev. Res.* 77, 427–436. doi: 10.1002/ddr.21338

Wijenayake, S., Hawkins, L. J., and Storey, K. B. (2018). Dynamic regulation of six histone H3 lysine (K) methyltransferases in response to prolonged anoxia exposure in a freshwater turtle. *Gene* 649, 50–57. doi: 10.1016/j.gene.2018.01.086

Xu, M., Chung, S., Zhang, S., Zhong, P., Ma, C., Chang, W. C., et al. (2015). Basal forebrain circuit for sleep-wake control. *Nat. Neurosci.* 18, 1641–1647. doi: 10.1038/nn.4143

Zaghoul, N., Addorissio, M. E., Silverman, H. A., Patel, H. L., Valdés-Ferrer, S. I., Ayasolla, K. R., et al. (2017). Forebrain cholinergic dysfunction and systemic and brain inflammation in murine sepsis survivors. *Front. Immunol.* 8:1673. doi: 10.3389/fimmu.2017.01673

Zaidi, S. K., Frietze, S. E., Gordon, J. A., Heath, J. L., Messier, T., Hong, D., et al. (2017). Rivalent epigenetic control of oncfoetal gene expression in cancer. *Mol. Cell. Biol.* 37:e352-17. doi: 10.1128/MCB.00352-17

Zam, W., and Khadour, A. (2017). Impact of phytochemicals and dietary patterns on epigenome and cancer. *Nutr. Cancer* 69, 184–200. doi: 10.1080/01635581.2017.1263746

Zhao, W. N., Ghosh, B., Tyler, M., Lalonde, J., Joseph, N. F., Kosaric, N., et al. (2018). Class I histone deacetylation inhibition by tianeptinamine modulates neuroplasticity and enhances memory. *ACS Chem. Neurosci.* 9, 2262–2273. doi: 10.1021/acschemneuro.8b00116

Zheng, S., Xiao, L., Liu, Y., Wang, Y., Cheng, L., Zhang, J., et al. (2018). DZNep inhibits H3K27me3 deposition and delays retinal degeneration in the rd1 mice. *Cell. Death Dis.* 9:310. doi: 10.1038/s41419-018-0349-8

Zhou, E. S., Clark, K., Recklitis, C. J., Obenchain, R., and Loscalzo, M. (2018). Sleepless from the get go: sleep problems prior to initiating cancer treatment. *Int. J. Behav. Med.* 25, 502–516. doi: 10.1007/s12529-018-9715-2

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Murillo-Rodriguez, Arankowsky-Sandoval, Barros, Rocha, Yamamoto, Machado, Budde, Telles-Correia, Monteiro, Cid and Veras. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.